Magnetically guided delivery of DHA and Fe ions for enhanced cancer therapy based on pH-responsive degradation of DHA-loaded Fe3O4@C@MIL-100(Fe) nanoparticles.
Dihydroartemisinin (DHA) has been investigated in cancer therapy for its reactive oxygen species (ROS) based cytotoxicity originated from interacting with ferrous ions that may reduce or eliminate the multidrug resistance commonly associated with conventional chemotherapy agents. However, synchronously delivery of hydrophobic DHA and Fe (Ⅲ) ions into tumor cells remains a major challenge. In this work, we develop novel Fe3O4@C@MIL-100(Fe) (FCM) nanoparticles for synchronously delivery of DHA and Fe (Ⅲ) for cancer therapy. The MOFs structure based on Fe (Ⅲ) carboxylate materials MIL-100 (Fe) holds great potential for storage/delivery of hydrophobic drug DHA. As a unique nanoplatform, the hybrid inorganic-organic drug delivery vehicles show pH-responsive biodegradation and synchronous releasing of DHA and Fe (Ⅲ) upon reaching tumor sites. The intracellular Fe (Ⅲ) will be reduced further to ferrous ion and interact with DHA to increase its cytotoxicity. The potential of this alternative anti-tumor modality is demonstrated in vivo due to an increased intracellular accumulation of DHA in tumor and activated mechanism via co-release of DHA and Fe (Ⅲ), especially under the guidance of an external applied magnetic field.
Hefei National Laboratory for Physical Sciences at Microscale, Department of Materials Science & Engineering & Collaborative Innovation Center of Suzhou Nano Science and Technology, CAS High Magnetic Field Laboratory, University of Science and Technology of China, Hefei, 230026, China.
Dongdong
D
Wang
Anhui Key Laboratory for Cellular Dynamics and Chemical Biology, School of Life Sciences, University of Science and Technology of China, Hefei, 230027, China.
Jiajia
J
Zhou
Hefei National Laboratory for Physical Sciences at Microscale, Department of Materials Science & Engineering & Collaborative Innovation Center of Suzhou Nano Science and Technology, CAS High Magnetic Field Laboratory, University of Science and Technology of China, Hefei, 230026, China.
Ruhui
R
Chen
Hefei National Laboratory for Physical Sciences at Microscale, Department of Materials Science & Engineering & Collaborative Innovation Center of Suzhou Nano Science and Technology, CAS High Magnetic Field Laboratory, University of Science and Technology of China, Hefei, 230026, China.
Ruohong
R
Shi
Hefei National Laboratory for Physical Sciences at Microscale, Department of Materials Science & Engineering & Collaborative Innovation Center of Suzhou Nano Science and Technology, CAS High Magnetic Field Laboratory, University of Science and Technology of China, Hefei, 230026, China.
Guoliang
G
Xia
Anhui Key Laboratory for Cellular Dynamics and Chemical Biology, School of Life Sciences, University of Science and Technology of China, Hefei, 230027, China.
Shu
S
Zhou
Anhui Key Laboratory for Cellular Dynamics and Chemical Biology, School of Life Sciences, University of Science and Technology of China, Hefei, 230027, China.
Zhenbang
Z
Liu
The First Affiliated Hospital of Bengbu Medical College, Bengbu, 233000, China.
NianQing
N
Zhang
Radiology Department of the First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China. Electronic address: whblqh@mail.ustc.edu.cn.
Haibao
H
Wang
Anhui Key Laboratory for Cellular Dynamics and Chemical Biology, School of Life Sciences, University of Science and Technology of China, Hefei, 230027, China. Electronic address: zhenguo@ustc.edu.cn.
Zhen
Z
Guo
Hefei National Laboratory for Physical Sciences at Microscale, Department of Materials Science & Engineering & Collaborative Innovation Center of Suzhou Nano Science and Technology, CAS High Magnetic Field Laboratory, University of Science and Technology of China, Hefei, 230026, China. Electronic address: cqw@ustc.edu.cn.
Qianwang
Q
Chen
D065966:Absorption, Physicochemical; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000737:chemistry; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D037621:Artemisinins / Q000008:administration & dosage / Q000737:chemistry; D016503:Drug Delivery Systems / Q000379:methods*; D004357:Drug Synergism; D005260:Female; D052203:Ferrosoferric Oxide / Q000737:chemistry* / Q000528:radiation effects; D006367:HeLa Cells; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007477:Ions / Q000008:administration & dosage / Q000737:chemistry; D007501:Iron / Q000008:administration & dosage / Q000737:chemistry; D060526:Magnetic Fields; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D053769:Nanocapsules / Q000737:chemistry* / Q000528:radiation effects; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D037621:Artemisinins; D007477:Ions; D053769:Nanocapsules; C039060:artenimol; D007501:Iron; D052203:Ferrosoferric Oxide
Biodegradable; Cancer therapy; DHA; MOFs; ROS